FDA Device Decisions, February 2026: An AI That Predicts Delivery Dates, Two De Novo Grants and Five Original PMAs
One of FDA's two De Novo grants in February 2026 went to Delivery Date AI (DEN250007), software that uses machine learning on pregnancy ultrasound images to predict the delivery date. It is meant for pregnant women without a reliable estimated delivery date, for example because the last menstrual period is uncertain and there was no first-trimester ultrasound.
The new classification's special controls include a postmarket performance management plan. Keeping track of how the software performs in real-world use, after authorization, is a condition of the classification.
Counting records held in RA Craft Database (decisions through August 31, 2026, tallied October 6), FDA cleared 215 510(k)s in February 2026, granted 2 De Novo requests and approved 5 original PMAs. These counts have not been reconciled with FDA's own figures. The site holds 510(k), De Novo and PMA records from 2015 onward, and counts for past months can change as the data are updated.
Counts by pathway
February 2026 next to the previous month and the same month a year earlier, with records assigned to a month by FDA decision date.
| Pathway | February 2026 | January 2026 | February 2025 |
|---|---|---|---|
| 510(k) | 215 | 236 | 232 |
| De Novo | 2 | 2 | 0 |
| PMA (original) | 5 | 2 | 2 |
| PMA supplement | 244 | 134 | 194 |
Records held in RA Craft Database, decisions through August 31, 2026.
510(k) clearances were 21 fewer than in January and below February 2025 (232). The 5 original PMAs compare with 2 in January and 2 a year earlier.
The busiest product codes
February's 510(k)s spread across 141 product codes. OLO (orthopedic stereotaxic instrument) led with 10, followed by GEX (powered laser surgical instrument) with 6 and DQK (computer, diagnostic, programmable) and HRS (plate, fixation, bone) with 5 each. Seven codes had 4: DXN, GCJ, HGX, LLZ, LNH, OWN and QIH. A single 510(k) can carry more than one product code, so per-code counts can add up to more than the number of submissions. If your code is on the list, enter it in the Product Code field on Search to see the records sorted by decision date.
De Novo: an antimicrobial dressing and delivery date software
February's two De Novo grants, both Class II, with the classification names and regulation numbers from each Classification Order:
- Amferia Wound Dressing (DEN250006, Amferia AB): Solid wound dressing with permanently bound antimicrobial agent (21 CFR 878.4013)
- Delivery Date AI (DEN250007, Ultrasound AI): Radiological software system for delivery date prediction (21 CFR 892.8200)
"21 CFR" refers to Title 21 of the Code of Federal Regulations, where FDA's regulations are codified.
Amferia is a dressing with an antimicrobial agent permanently bound to its surface, for covering and protecting dry-to-low-exuding wounds such as abrasions, surgical wounds, superficial burns and pressure ulcers. Its special controls exclude medically important antimicrobials and require an evaluation of the device's possible contribution to the development and spread of antimicrobial resistance. It is an example of antimicrobial stewardship written into a device classification.
Original PMAs: five approvals
- Optimum Infinite Orthokeratology Lenses II (P240045, Contamac, Ltd.): overnight orthokeratology lenses for temporary reduction of myopia (product code NUU)
- Optune Pax (P250034, Novocure GmbH): Tumor Treating Fields for locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel (SHC)
- LimiFlex Dynamic Sagittal Tether (P220031, Empirical Spine, Inc.): a motion-preserving spinous process tether used after decompression for degenerative spondylolisthesis with spinal stenosis, as an alternative to fusion (SGK)
- Allurion Gastric Balloon System (P250023, Allurion Technologies, Inc.): a swallowed intragastric balloon that empties and passes naturally (LTI)
- Synergy Disc (P250028, Synergy Spine Solutions, Inc.): a single-level cervical artificial disc (MJO)
February also brought 244 PMA supplements, which cover changes to already approved PMA devices among other things.
Three devices worth a closer read
1. Delivery Date AI (DEN250007, De Novo). For singleton pregnancies from 14 0/7 to 36 6/7 weeks in women 18 and older without a reliable estimated delivery date, the software produces a predicted delivery date from ultrasound images. The classification's identification states that the output does not replace a clinician's judgment and that the device does not identify at-risk pregnancies or complications. One of the five special controls is a postmarket performance management plan: monitor real-world performance, detect and explain changes, assess their impact, and tell users how the device currently performs.
2. Optune Pax (P250034, PMA). The device delivers 150 kHz alternating electric fields through arrays on the abdomen to disrupt cancer cell division, alongside chemotherapy for locally advanced pancreatic cancer. According to the Summary of Safety and Effectiveness Data (SSED) that FDA published with the approval, median overall survival in the randomized PANOVA-3 trial was 16.2 months with the device plus chemotherapy and 14.2 months with chemotherapy alone. It received Breakthrough Device designation in December 2024.
3. Optimum Infinite Orthokeratology Lenses II (P240045, PMA). Approved without a new clinical study. The applicant relied on clinical data from another company's PMA for a lens of the same material and design (P050031), under the provision that lets FDA use data from a PMA approved more than six years earlier, often called the six-year rule. Even a PMA can rest on existing clinical data when the conditions are met.
Compare the three devices
Open DEN250007, P250034 and P240045, star (☆) each one, tick "Compare" on all three in My Workspace and press "3 selected for comparison". The comparison table puts their Indications for Use side by side. Before relying on any of this, open "FDA Record" and "Summary PDF" on each record and read the source.
Note: months are assigned by FDA decision date, and counts can change as the data are updated each month.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles